The effect of preoperative gemcitabine and nab-Paclitaxel compared to historical controls on RO surgical rate in patients with resectable pancreas cancer

AGITG0 个研究点目标入组 50 人开始时间: 2011年8月10日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Males or females with histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the pancreas. In those patients with histology or cytology highly suspicious for adenocarcinoma, the diagnosis of pancreatic adenocarcinoma will be made by integrating this histological data with the clinical and radiographic data (tumour mass visible on three phase CT scan (or MRI scan) of the pancreas). Patients with islet cell neoplasms are excluded;
•-Disease is clearly resectable on the basis of physical examination and the following objective CT criteria (or MRI if indicated):
•(i) no evidence of extra-pancreatic disease;
•(ii) no evidence of tumour abutment of the superior mesenteric artery (SMA) or coeliac axis (T4); and
•(iii) no evidence of portal vein infiltration of more than 180 degrees of the circumference or occlusion of the superior mesenteric vein (SMV) or SMV–portal vein (PTV) confluence.

•- Patient considered to have a borderline resectable tumour.
•- Patients with locally advanced disease.
•- Evidence of systemic disease (cardiovascular, renal, hepatic, etc.) that would preclude surgery, chemotherapy or chemoradiotherapy.
•- Concurrent illness including severe infection that may jeopardize the ability of the patient to undergo the procedures outlined in this protocol with reasonable safety.

发起方

AGITG